Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Bunnell, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Bunnell, Inc.

Regulatory records
4
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 4 FDA records to the applicant name Bunnell, Inc.. It includes 1 original PMA approval. 2 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jun 30, 1988 to Sep 28, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code LSZ appears in 4 of the 4 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P850064, with 4 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 436 Lawndale Dr., Salt Lake City, UT, 84115. Recorded on P850064/S056, decision dated Sep 28, 2026.

Changes described in PMA records

P850064/S056: LifePulse High Frequency Ventilator

The FDA's Center for Devices and Radiological Health completed review of a premarket approval application 180-day supplement for the LifePulse High Frequency Ventilator, product code LSZ, submitted by Bunnell, Inc. The supplement is logged under P850064/S056, and its stated reason is a labeling change covering indications, instructions, shelf life or tradename; the decision recorded is approval. The action concerns the device's Indications for Use, not a new approval of the whole system.

The approved updated IFU reads that the device is indicated for treating pediatric patients, including neonates, who require temporary ventilatory support for acute respiratory failure. The statement also assigns the clinician responsibility for determining appropriate use and for considering the patient's respiratory status and general health when setting ventilator settings. The database entry does not describe the prior IFU wording, the basis for the change, or any clinical data, so the degree of change from the earlier labeling remains unspecified.

FDA approval-order wording

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) 180-day supplement, which requested approval for an update to the Indications for Use (IFU). The approved updated IFU will read: The LifePulse High Frequency Ventilator is indicated for treating pediatric patients (including neonates) who require temporary ventilatory support for acute respiratory failure. It is the responsibility of the clinician to determine the appropriate use of the LifePulse High Frequency Ventilator. The user needs to consider the respiratory status and the general state of health of the patient in order to optimally set ventilator settings for the patients condition(s).

Sep 28, 2026 · Normal 180 Day Track

P850064/S058: LifePulse High Frequency Ventilator (LifePulse HFV) Model 204

FDA’s recorded scope: This is a 30-DN to provide the change in power cord testing as a result of a CAPA investigation into a miswiring of one single power cord. the testing is adequate to test the incoming inspection for cross-wired power cords and not as a complete safety check.

May 7, 2026 · 30-Day Notice

P850064/S055: LifePulse High Frequency Ventilator (HFV)

FDA’s recorded scope: for a change to materials in the Patient Circuit based on their biocompatibility profile. The changes include: a change to circuit tubing material (no change to tubing type or dimensions), change in the anodization process of the heater cup, and replacing the adhesives used with medical grade adhesives.

Jul 25, 2025 · Real-Time Process

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Bunnell, Inc.PMA supplementSep 28, 2026FDA
Bunnell, Inc.PMA supplementMay 7, 2026FDA
Bunnell, Inc.PMA supplementJul 25, 2025FDA
Bunnell, Inc.PMA approvalJun 30, 1988FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 20, 2026.